EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Applied BioCode (6598) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Applied BioCode TWD 4.05, price TWD 27.30, upside -85.2%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW · ISIN KYG0488D1051

AB Thin data Sep 24, 2026

Applied BioCode

6598 · TW

Weakest SetupStrongly overvalued and low quality.

!Fair value 4.05 TWD · Strongly overvalued (−85%)
!Quality 47/100
!Expensive Growth (revenue 5y +9.7 %/yr)
!Loss-making · -25.3% net margin (TTM)
!Low debt · negative free cash flow
!Mixed vs. peers (5/10)
!Narrow moat 21/100
!Evidence only low, so the estimate is less certain
Watch Applied BioCode for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

56.80 TWD 17.45 TWD Fair Value 4.05 TWD Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 17.45 TWD – 56.80 TWD · fair‑value band 2.67 TWD – 5.05 TWD · the 27.30 TWD price screens above the 4.05 TWD fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Applied BioCode in your weekly email

Every Wednesday you see whether Applied BioCode is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California.

Show more

Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity. The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; and CoV-2 Flu Assay for detection of RNA and various Influenza, as well as offers gastrointestinal and respiratory pathogen panel related products. In addition, it provides BioCode Fungal Panel, a multiplexed deoxyribonucleic acid (DNA) amplification test; and BioCode STI + Resistance Panel (RUO), a multiplex nucleic acid amplification test. Further, the company offers barcoded magnetic bead accessories. Applied BioCode Corporation was founded in 2016 and is based in Grand Cayman, the Cayman Islands.

Stock analysis

Applied BioCode (6598) currently trades at 27.30 TWD, while our model-based Fair Value estimate is 4.05 TWD, implying the stock looks roughly 574.8% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 2.67 TWD (bear) to 5.05 TWD (bull), the price of 27.30 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Applied BioCode reported revenue of 475M TWD in FY2025 versus 320M TWD in FY2021, a compound +10.4%/yr. Reported net income was −201M TWD in FY2025.

Key figures

Market cap 2.8B TWD (≈ $88.0M) · P/S ratio 4.79 · EPS (TTM) −1.96 TWD · Net margin −42.3% · Return on equity −18.9% · Return on assets (EBIT) −18.9% · Operating margin 8.3% · Revenue (TTM) 572M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (medium confidence).

What moves the price

The share trades about 13% below its 52-week high and 33% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −85%, 6598 screens richer than that median.

Fair Value models

Bear 2.67 TWD Fair Value 4.05 TWD Bull 5.05 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 3.13 TWD 4.19 TWD 6.26 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 3.13 TWD 4.19 TWD 6.26 TWD 54

Open the full fair value analysis →

Notify me when 6598 reaches fair value

Put 6598 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 47/100

Of which business quality 47 · Market factors (momentum, volatility) 62

Profitability 15
Margins and returns on capital today
Quality Growth 74
Are margins and returns improving?
Cashflow 14
Earnings quality: real cash, not paper profit
Fin. Strength 99
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 67
Calm price path (market factor)
Momentum 60
Price trend over the last 3–12 months (market factor)
52W Momentum 58
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+38.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
Start year 2020 (pandemic). Over 10 years: +35.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−33.2% (2020) → −47.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6598 screens 575% overvalued. Compare with Abbott Laboratories, →

Compare Applied BioCode with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −85% · Bottom 25%
Profitability
Return on assets −9% · Below median
Net margin (TTM) −25% · Bottom 25%
Operating margin (TTM) 8% · Above median
Growth and dividend
Revenue growth 81% · Top 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.14× · Cheapest 25%
P/S (TTM) 0.15× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 10
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)0 · sector 7
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 40

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.69 $74.79 −28%
Stryker Corporation SYK $275.09 $302.60 +10%
Medtronic plc MDT $90.77 $65.57 −28%
Boston Scientific Corporation BSX $44.92 $49.41 +10%
Edwards Lifesciences Corporation EW $88.78 $82.04 −8%
Siemens Healthineers AG SHL €37.43 €35.22 −6%
DexCom, Inc DXCM $89.53 $98.48 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Applied BioCode · Fair Value
4.05 TWD −575%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Applied BioCode Fair Value". https://www.fairvalue-calculator.com/stock/6598

Frequently asked questions

Is Applied BioCode (6598) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 4.05 TWD versus a price of 27.30 TWD, about −85% upside (overvalued).
What is the fair value of 6598?
Our model-based fair value for Applied BioCode is 4.05 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 27.30 TWD.
What is the quality score of 6598?
Applied BioCode has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Applied BioCode (6598)?
Our model-based price target is the fair value of 4.05 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 2.67 TWD, optimistic scenario 5.05 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Applied BioCode stock forecast for 2026?
Our models put fair value at 4.05 TWD, about −85% upside versus a price of 27.30 TWD (overvalued). Cautious scenario 2.67 TWD, optimistic scenario 5.05 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Applied BioCode (6598)?
Applied BioCode reported trailing-twelve-month revenue of about 572M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Applied BioCode (6598)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Applied BioCode it is 4.05 TWD per share (as of Sep 24, 2026), against a price of 27.30 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Applied BioCode stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6598 trades above its calculated fair value: price 27.30 TWD, fair value 4.05 TWD, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6598?
No. The price is what the market pays today (27.30 TWD); the fair value is what the company's own numbers justify (4.05 TWD). For Applied BioCode the two are 23.25 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Applied BioCode worth?
The market values Applied BioCode at about 2.8B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 27.30 TWD; our models calculate a fair value of 4.05 TWD per share.
What do the bullish and bearish scenarios say about 6598?
Our models span a range for Applied BioCode: cautious scenario 2.67 TWD, base 4.05 TWD, optimistic 5.05 TWD per share (as of Sep 24, 2026, price 27.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Applied BioCode (6598)?
Balance-sheet figures for Applied BioCode (as of Sep 24, 2026): return on equity −18.9%, debt of 0.01 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 6598 from its 52-week high?
Applied BioCode trades at 27.30 TWD, about 13% below its 52-week high of 31.35 TWD and 33% above the low of 20.55 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 4.05 TWD is for.
Which stocks are comparable to Applied BioCode?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Applied BioCode stock attractive at the current price?
The data as of Sep 24, 2026: price 27.30 TWD, calculated fair value 4.05 TWD (−85%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6598 calculated?
We run Applied BioCode through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4.05 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Applied BioCode itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Applied BioCode (6598)?
The closing price on Sep 24, 2026 was 27.30 TWD. Our model-based fair value is 4.05 TWD, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Applied BioCode right now?
The price sits above even our optimistic bull case (5.05 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (2.67 TWD to 5.05 TWD) leaves room in how you read the outcome.

Key figures of Applied BioCode

How large is the market capitalisation of Applied BioCode (6598)?
The market capitalisation of Applied BioCode is 2.8B TWD (≈ $88.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Applied BioCode (6598)?
The price-to-sales ratio of Applied BioCode is 4.79 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Applied BioCode (6598)?
Earnings per share at Applied BioCode are −1.96 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Applied BioCode (6598)?
The net margin of Applied BioCode is −42.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Applied BioCode (6598)?
The return on equity (ROE) of Applied BioCode is −18.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Applied BioCode (6598)?
On an EBIT basis the return on assets of Applied BioCode is −18.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Applied BioCode (6598)?
The operating margin of Applied BioCode is 8.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Applied BioCode (6598)?
Revenue at Applied BioCode is growing +80.9% versus a year earlier (3y avg +6.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Applied BioCode (6598) generate?
The free cash flow of Applied BioCode is −235M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Applied BioCode (6598) hold?
Applied BioCode holds more cash than debt, 405M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Applied BioCode in the live analysis

One click puts Applied BioCode on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.